ITEM VIEW

Priority areas for cannabis and cannabinoid product research in South Africa

dc.contributor.authorAugustine, Tanya N.en_ZA
dc.contributor.authorCairns, Carel J.en_ZA
dc.contributor.authorChetty, Seanen_ZA
dc.contributor.authorDannatt, Lisa G.en_ZA
dc.contributor.authorGravett, Nadineen_ZA
dc.contributor.authorGrey, Glendaen_ZA
dc.contributor.authorGrobler, Gerharden_ZA
dc.contributor.authorJafta, Zukiswaen_ZA
dc.contributor.authorKamerman, Peteren_ZA
dc.contributor.authorLopes, Johnen_ZA
dc.contributor.authorMatsabisa, Motlalepula G.en_ZA
dc.contributor.authorMugabo, Pierreen_ZA
dc.contributor.authorMulder, Michelleen_ZA
dc.contributor.authorParry, Charlesen_ZA
dc.contributor.authorRataemane, Solomonen_ZA
dc.contributor.authorSiegfried, Nandien_ZA
dc.contributor.authorSteenkamp, Vanessaen_ZA
dc.contributor.authorThomas, Eileenen_ZA
dc.contributor.authorVan Zyl-Smit, Richarden_ZA
dc.date.accessioned2019-09-05T07:15:05Z
dc.date.available2019-09-05T07:15:05Z
dc.date.issued2018-06
dc.identifier.citationAugustine, T.N. et al. 2018. Priority areas for cannabis and cannabinoid product research in South Africa. African Journal of Primary Health Care & Family Medicine, 10(1):1-3, doi:10.4102/phcfm.v10i1.1711.en_ZA
dc.identifier.issn2071-2936 (online)
dc.identifier.issn2071-2928 (print)
dc.identifier.otherdo:10.4102/phcfm.v10i1.1711
dc.identifier.urihttp://hdl.handle.net/10019.1/106424
dc.descriptionCITATION: Augustine, T.N. et al. 2018. Priority areas for cannabis and cannabinoid product research in South Africa. African Journal of Primary Health Care & Family Medicine, 10(1):1-3, doi:10.4102/phcfm.v10i1.1711.en_ZA
dc.descriptionThe original publication is available at https://phcfm.org/index.php/phcfmen_ZA
dc.description.abstractThe legalisation of cannabis for medicinal use is a contentious space both politically and in the medical community. In 2014, the Medical Innovation Bill introduced by Mario Oriani-Ambrosini MP, aimed to shift the political and legal positions of cannabis as an illegal substance to one available for research and medical use. To date, progress on this has been slow. Cannabis and cannabinoid products are currently available for medicinal use in several countries, including the Netherlands and 29 states in the United States. Locally, anecdotal reports suggest that many of our patients with chronic medical conditions are using cannabis and cannabis-derived or cannabinoid products for symptom alleviation.en_ZA
dc.description.urihttps://phcfm.org/index.php/phcfm/article/view/1711en_ZA
dc.language.isoen_ZAen_ZA
dc.publisherAOSISen_ZA
dc.subjectCannabisen_ZA
dc.subjectMedicinal cannabisen_ZA
dc.subjectHIVen_ZA
dc.subjectSensory neuropathen_ZA
dc.subjectChronic painen_ZA
dc.subjectCannabis policyen_ZA
dc.titlePriority areas for cannabis and cannabinoid product research in South Africaen_ZA
dc.typeArticleen_ZA
dc.description.versionPublishers versionen_ZA
dc.rights.holderAuthors retain copyrighten_ZA


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

ITEM VIEW